{"id":17251,"date":"2021-04-21T10:24:18","date_gmt":"2021-04-21T08:24:18","guid":{"rendered":"https:\/\/idibell.cat\/?p=17251"},"modified":"2024-11-27T12:06:16","modified_gmt":"2024-11-27T11:06:16","slug":"lidibell-i-lhospital-de-bellvitge-lideren-un-estudi-sobre-lefectivitat-de-licatibant-contra-la-covid-19","status":"publish","type":"post","link":"https:\/\/idibell.cat\/2021\/04\/lidibell-i-lhospital-de-bellvitge-lideren-un-estudi-sobre-lefectivitat-de-licatibant-contra-la-covid-19\/","title":{"rendered":"L\u2019IDIBELL i l\u2019Hospital de Bellvitge lideren un estudi sobre l\u2019efectivitat de l\u2019Icatibant contra la Covid-19"},"content":{"rendered":"<p>Aquesta investigaci\u00f3 es troba en fase de reclutament i inclour\u00e0 <strong>120 pacients<\/strong> de diversos hospitals espanyols. Est\u00e0 previst que els primers resultats es coneguin al novembre.<\/p>\n<p><strong>Icatibant<\/strong> est\u00e0 autoritzat per al tractament de l\u2019angioedema hereditari, un trastorn d\u2019origen gen\u00e8tic que causa crisis recurrents d&#8217;edema (inflor) debilitant i dolor a diverses parts del cos, que poden arribar a resultar letals. El f\u00e0rmac podria exercir dos possibles mecanismes d&#8217;acci\u00f3 contra la Covid-19. D&#8217;una banda, bloquejaria l&#8217;acci\u00f3 de la bradicinina augmentada a la Covid-19 i, de l&#8217;altra, inhibiria la proteasa M de la SARS-CoV-2, que \u00e9s clau en la replicaci\u00f3 de virus.<\/p>\n<p>\u201c<em>La pand\u00e8mia causada per la Covid-19 ha colpejat amb duresa a nivell mundial i cal investigar per proporcionar les millors opcions terap\u00e8utiques per als pacients. Aix\u00f2 ens ha impulsat a iniciar moltes investigacions, entre les quals el primer assaig cl\u00ednic que es realitza a nivell mundial sobre Icatibant en pacients infectats per SARS-CoV-2<\/em>\u201d, comenta el cap de Departament d&#8217;Investigaci\u00f3 Cl\u00ednica de l&#8217;<a href=\"https:\/\/idibell.cat\/\">IDIBELL<\/a>, el <strong>Dr. Sebasti\u00e0 Videla<\/strong>.<\/p>\n<p>La poblaci\u00f3 objectiu d&#8217;aquest assaig cl\u00ednic la constitueixen els pacients hospitalitzats diagnosticats de pneum\u00f2nia per la SARS-CoV-2 que es troben sense ventilaci\u00f3 mec\u00e0nica invasiva. &#8220;<em>Es considerar\u00e0 \u00e8xit el cas dels pacients que, en el des\u00e8 dia de tractament amb Icatibant, el seu estat cl\u00ednic hagi millorat del grau 4 o 5 al grau 2 o inferior i no hagin presentat reaccions adverses rellevants<\/em>&#8220;, explica el <strong>Dr. Jordi Giol<\/strong>, facultatiu especialista del Servei d\u2019Urg\u00e8ncies de l&#8217;Hospital de Bellvitge.<\/p>\n<p>\u201c<em>Identificar opcions terap\u00e8utiques efectives per al tractament i la prevenci\u00f3 de la Covid-19 \u00e9s un dels grans reptes m\u00e8dics actuals, per si apareixen variants que escapen a les vacunes o per a persones que, per alguna contraindicaci\u00f3, no es puguin vacunar<\/em>\u201d, assenyala la directora m\u00e8dica, de regulador i qualitat de Takeda Espanya, la <strong>Dra. Carmen Montoto<\/strong>.<\/p>\n<p>&nbsp;<\/p>\n<p>&nbsp;<\/p>\n<p>&nbsp;<\/p>\n<p><em>L\u2019Institut d&#8217;Investigaci\u00f3 Biom\u00e8dica de Bellvitge (IDIBELL) \u00e9s un centre de recerca en biomedicina creat l\u2019any 2004. Est\u00e0 participat per l&#8217;Hospital Universitari de Bellvitge i l\u2019Hospital de Viladecans de l&#8217;Institut Catal\u00e0 de la Salut, l&#8217;Institut Catal\u00e0 d&#8217;Oncologia, la Universitat de Barcelona i l\u2019Ajuntament de l\u2019Hospitalet de Llobregat.<\/em><\/p>\n<p><em>L\u2019IDIBELL \u00e9s membre del Campus d&#8217;Excel\u00b7l\u00e8ncia Internacional de la Universitat de Barcelona HUBc i forma part de la instituci\u00f3 CERCA de la Generalitat de Catalunya. L&#8217;any 2009 es va convertir en un dels cinc primers centres d\u2019investigaci\u00f3 espanyols acreditats com a institut d\u2019investigaci\u00f3 sanit\u00e0ria per l\u2019Instituto de Salud Carlos III. A m\u00e9s, forma part del programa \u201cHR Excellence in Research\u201d de la Uni\u00f3 Europea i \u00e9s membre de EATRIS i REGIC. Des de l\u2019any 2018, l\u2019IDIBELL \u00e9s un Centro Acreditado de la Fundaci\u00f3n Cient\u00edfica AECC (FCAECC).<\/em><\/p>\n","protected":false},"excerpt":{"rendered":"<p>l&#8217;Institut d&#8217;Investigaci\u00f3 Biom\u00e8dica de Bellvitge (IDIBELL) amb l\u2019Hospital Universitari de Bellvitge, ha iniciat un estudi cl\u00ednic, en col\u00b7laboraci\u00f3 amb la companyia farmac\u00e8utica Takeda, per avaluar l\u2019efic\u00e0cia i seguretat de l\u2019Icatibant com a tractament contra la Covid-19.<\/p>\n","protected":false},"author":8,"featured_media":17252,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"site-sidebar-layout":"default","site-content-layout":"default","ast-site-content-layout":"default","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"default","adv-header-id-meta":"","stick-header-meta":"default","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"set","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"footnotes":""},"categories":[493,520],"tags":[],"class_list":["post-17251","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-innovacio","category-processos-urgents-i-emergents"],"publishpress_future_action":{"enabled":false,"date":"2024-12-30 08:23:54","action":"change-status","newStatus":"draft","terms":[],"taxonomy":"category"},"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/posts\/17251","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/users\/8"}],"replies":[{"embeddable":true,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/comments?post=17251"}],"version-history":[{"count":1,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/posts\/17251\/revisions"}],"predecessor-version":[{"id":26674,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/posts\/17251\/revisions\/26674"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/media\/17252"}],"wp:attachment":[{"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/media?parent=17251"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/categories?post=17251"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/tags?post=17251"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}